Dec 09, 2020
News
At NGM, we pride ourselves on conducting world-class science and sharing our research efforts with the broader scientific and medical communities.
Nov 16, 2020
NGM to Host Virtual R&D Day on December 9, 2020
Nov 13, 2020
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual
Nov 12, 2020
NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results
Nov 11, 2020
NGM Bio to Present at Three Upcoming Investor Conferences
Nov 05, 2020
NGM Bio to Present Safety and Pharmacokinetics Data from Phase 1 Study of NGM621 in Patients with Geographic Atrophy at American Academy of Ophthalmology (AAO) 2020 Virtual
Nov 04, 2020
NGM Bio Announces Multiple Aldafermin Presentations at Upcoming AASLD The Liver Meeting®, including Late-Breaking Oral Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH
Oct 19, 2020
NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4
Aug 29, 2020
NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study
Aug 18, 2020
NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH at The Digital International Liver Congress™ (ILC) 2020
Aug 12, 2020
NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results
Jul 31, 2020
NGM Bio to Present at Two Upcoming Investor Conferences
Jul 27, 2020
NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Jun 08, 2020
NGM Bio Expands Board of Directors with Appointment of Carole Ho, M.D.
May 29, 2020
NGM Bio to Present at Two Upcoming Investor Conferences
May 27, 2020
NGM Bio Appoints Siobhan Nolan Mangini as Chief Financial Officer
May 13, 2020
NGM Bio Provides Business Update and Reports First Quarter 2020 Financial Results
May 08, 2020
NGM Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
Mar 17, 2020
NGM Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
Mar 09, 2020
Aetna Wun Trombley, Ph.D. to Step Down as President and Chief Operating Officer of NGM Bio to Assume Chief Executive Officer Role at Undisclosed Privately Held Company
Feb 25, 2020
NGM Bio to Present at Cowen and Company 40th Annual Health Care Conference
Feb 24, 2020
NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and Resolution of NASH versus Placebo
Feb 23, 2020
NGM Bio to Host Conference Call to Discuss Preliminary Topline Results, Including Histology Data, from 24-Week Phase 2 Study of Aldafermin in Patients with NASH
Feb 11, 2020